Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Capital Expenditures (2016 - 2025)

Icu Medical (ICUI) has disclosed Capital Expenditures for 17 consecutive years, with $82.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 9.49% year-over-year to $82.5 million, compared with a TTM value of $88.0 million through Dec 2025, up 10.92%, and an annual FY2025 reading of $88.0 million, up 10.92% over the prior year.
  • Capital Expenditures was $82.5 million for Q4 2025 at Icu Medical, up from -$28.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $82.5 million in Q4 2025 and bottomed at -$63.9 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $16.2 million, with a median of $16.5 million recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 3747.41% in 2025, while the deepest fall reached 18783.77% in 2025.
  • Year by year, Capital Expenditures stood at $65.6 million in 2021, then crashed by 197.28% to -$63.9 million in 2022, then skyrocketed by 225.56% to $80.2 million in 2023, then dropped by 6.02% to $75.4 million in 2024, then increased by 9.49% to $82.5 million in 2025.
  • Business Quant data shows Capital Expenditures for ICUI at $82.5 million in Q4 2025, -$28.8 million in Q3 2025, and $19.7 million in Q2 2025.